Intuitive Surgical Inc stock (US4612021034): valuation metrics in focus after recent price weakness

Intuitive Surgical shares on the Nasdaq have come under pressure, trading around USD 418, while valuation metrics such as a P/E ratio above 50 keep attention on how the United States-based robotic surgery pioneer is priced versus its growth outlook.

Intuitive Surgical, the United States-based medical technology group behind the da Vinci surgical robot, continues to see its Nasdaq-listed shares consolidate near the lower end of their recent range, with the price quoted at about USD 418.55 in late May 2026 according to Nasdaq and guru-focused price data as of 05/27/2026, after a drop of roughly 4.1% on that day that put further pressure on the stock in its home market.

The stock, which trades on Nasdaq under the ticker ISRG in USD and forms part of the broader US healthcare and technology complex, is being closely watched by investors in the United States as valuation multiples remain elevated despite the recent correction in the share price.

The shares opened around USD 418.55 and have been fluctuating between approximately USD 414.75 and USD 424.81 in recent sessions, with a 52-week range that stretches from about USD 414.58 on the downside to around USD 603.70 at the high, underscoring the extent of the pullback over the past months.

As of 05/27/2026, the market capitalization for Intuitive Surgical stands at roughly USD 148 billion, with the stock trading at a trailing price-earnings ratio of about 50.7 based on earnings per share near USD 8.25 to USD 8.30, according to data compiled from Nasdaq-linked statistics and MarketBeat.

The company remains listed on Nasdaq in the United States with no confirmed delisting or take-private transaction filed with the SEC, and US regulators continue to receive its periodic reports and any Form 8-K filings related to material events.

According to MarketBeat and other consensus data providers referencing sell-side models as of late May 2026, earnings for Intuitive Surgical are expected to grow by roughly the mid-teens percentage range year over year, with one consensus view seeing EPS rising around 14% next year from a base in the high single digits, which helps explain why US investors still assign a premium multiple to the stock even after the recent correction.

The price development in New York also feeds through to trading on German platforms used by retail investors: on Tradegate, Intuitive Surgical shares generally follow the Nasdaq line in euro terms, though local liquidity and spreads can vary during European hours when the US market is closed.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ISRG
• Sector/industry: Medical technology and robotic-assisted surgery
• Headquarters/country: Sunnyvale, United States
• Core markets: United States, Europe, Asia-Pacific hospitals
• Key revenue drivers: da Vinci surgical systems, instruments and accessories, service contracts
• Home exchange/listing venue: Nasdaq (ISRG)
• Trading currency: USD

Intuitive Surgical Inc: core business model

Focusing on robotic-assisted minimally invasive surgery, Intuitive Surgical generates most of its revenue by placing da Vinci systems with hospitals and then steadily monetizing a global installed base through disposable instruments, accessories, and maintenance services.

Valuation metrics and multiples for Intuitive Surgical Inc

With Friday's module focused on valuation, investors are paying close attention to how Intuitive Surgical is priced on Nasdaq after the stock's slide from its 52-week high near USD 603.70 to around USD 418.55 as of 05/27/2026, a move that has compressed but not eliminated the premium that the market assigns to the United States-based surgical robotics leader.

GuruFocus and MarketBeat data as of 05/27/2026 and 05/28/2026 indicate that the shares change hands at a trailing P/E ratio of about 50.7, with a price/earnings-to-growth (PEG) ratio quoted near 4 based on expected earnings expansion, and a price-to-sales multiple that remains substantially above the broader S&P 500 healthcare sector, reflecting expectations for sustained double-digit growth in procedures and system placements.

According to MarketBeat as of 05/28/2026, the stock also carries a consensus rating that corresponds to a "Moderate Buy" and an average price target around USD 576.71, implying that even after the correction there is a substantial percentage gap between the prevailing price level and the aggregated analyst fair-value estimates, though individual bank targets and methodologies can differ.

The company does not currently pay a regular cash dividend, so yield-based valuation metrics are not a factor in the investment case; instead, the market in the United States and in Germany tends to judge the share on growth-oriented multiples, balancing the high P/E and PEG against Intuitive Surgical's track record of increasing procedure volumes and expanding its installed base.

Conclusion

Intuitive Surgical's share price around USD 418.55 on Nasdaq places the company near the low end of its 52-week range, but the stock still trades at valuation multiples that are materially above broader US market averages, underscoring how the market continues to price in robust growth in robotic-assisted surgery.

With a trailing P/E above 50, a notable spread to the average analyst price target near USD 576.71, and no dividend, the investment debate in the United States and among German traders hinges on whether the company can deliver enough earnings expansion and procedure growth to support these metrics over time rather than on any income component.

For investors monitoring healthcare and medtech names, the balance between Intuitive Surgical's premium valuation and its operating momentum remains a central theme whenever the shares move meaningfully within their wide 52-week band.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.